Page last updated: 2024-11-01

ondansetron and Rheumatoid Arthritis

ondansetron has been researched along with Rheumatoid Arthritis in 2 studies

Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Research Excerpts

ExcerptRelevanceReference
"Rheumatoid arthritis, Methotrexate, Ondansetron, Nausea, Arthritis juvenile."4.12Role of Ondansetron in Reducing Methotrexate Intolerance in Patients with Inflammatory Arthritis. ( Fida, S; Kakalia, S; Khan, HA; Kitchlew, R; Saif, S; Siddique, M, 2022)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Saif, S1
Kakalia, S1
Kitchlew, R1
Khan, HA1
Fida, S1
Siddique, M1
Blanco, R1
González-Gay, MA1
García-Porrúa, C1
Ibañez, D1
García-Pais, MJ1
Sánchez-Andrade, A1
Vázquez-Caruncho, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis[NCT04169828]176 participants (Anticipated)Interventional2019-08-02Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for ondansetron and Rheumatoid Arthritis

ArticleYear
Ondansetron prevents refractory and severe methotrexate-induced nausea in rheumatoid arthritis.
    British journal of rheumatology, 1998, Volume: 37, Issue:5

    Topics: Antiemetics; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Nausea

1998

Other Studies

1 other study available for ondansetron and Rheumatoid Arthritis

ArticleYear
Role of Ondansetron in Reducing Methotrexate Intolerance in Patients with Inflammatory Arthritis.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2022, Volume: 32, Issue:10

    Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Humans; Methotrexate; Nausea; Onda

2022